Contact
searchSearch
HMP Global
Login

Gastrointestinal Cancers

Gastrointestinal Cancers
Specialty Channel
News
Zanidatamab Plus Tislelizumab Improves Survival in HER2-Positive Advanced Gastroesophageal Adenocarcinoma
06/10/2026
Emily Estrada
Results from the HERIZON-GEA-01 trial demonstrated that zanidatamab plus chemotherapy with or without tislelizumab significantly improved outcomes in patients with HER2-positive advanced gastroesophageal adenocarcinoma.
Results from the HERIZON-GEA-01 trial demonstrated that zanidatamab plus chemotherapy with or without tislelizumab significantly improved outcomes in patients with HER2-positive advanced gastroesophageal adenocarcinoma.
Results from the HERIZON-GEA-01...
06/10/2026
Oncology
Yelena Janjigian, MD
Videos
Five-Year Follow-Up Confirms Long-Term Survival Benefit With Nivolumab Plus Chemotherapy in Advanced Gastric Cancer
04/01/2026
Yelena Y. Janjigian, MD
Yelena Janjigian, MD, discusses the 5-year follow-up analysis of the phase 3 CheckMate 649 trial showing that first-line nivolumab plus chemotherapy continued to improve overall survival and progression-free survival in patients with advanced...
Yelena Janjigian, MD, discusses the 5-year follow-up analysis of the phase 3 CheckMate 649 trial showing that first-line nivolumab plus chemotherapy continued to improve overall survival and progression-free survival in patients with advanced...
Yelena Janjigian, MD, discusses...
04/01/2026
Oncology
News
Five-Year Follow-up Confirms Survival Benefit With Nivolumab Plus Chemotherapy in Gastroesophageal Adenocarcinoma
02/12/2026
Stephanie Holland
Five-year follow-up from the phase 3 CheckMate 649 trial demonstrated that nivolumab plus chemotherapy continued to improve survival compared with chemotherapy alone in patients with previously untreated, HER2-negative unresectable or...
Five-year follow-up from the phase 3 CheckMate 649 trial demonstrated that nivolumab plus chemotherapy continued to improve survival compared with chemotherapy alone in patients with previously untreated, HER2-negative unresectable or...
Five-year follow-up from the...
02/12/2026
Oncology
News
Anbenitamab Plus Chemotherapy Improves Survival After Trastuzumab in HER2-Positive Gastric and Gastroesophageal Junction Cancer
01/21/2026
Stephanie Holland
Results from a phase 3 trial demonstrated that anbenitamab plus chemotherapy significantly improved progression-free and overall survival compared with placebo plus chemotherapy in patients with previously treated HER2-positive gastric or...
Results from a phase 3 trial demonstrated that anbenitamab plus chemotherapy significantly improved progression-free and overall survival compared with placebo plus chemotherapy in patients with previously treated HER2-positive gastric or...
Results from a phase 3 trial...
01/21/2026
Oncology
News
Addition of Tislelizumab to Neoadjuvant Chemoradiotherapy Shows Clinical Promise for Gastric/GEJ Cancer
01/13/2026
Stephanie Holland
Phase 2b results from the TERRIFIC study demonstrate that neoadjuvant tislelizumab plus chemoradiotherapy shows clinical promise for locally advanced gastric or gastroesophageal junction cancer.
Phase 2b results from the TERRIFIC study demonstrate that neoadjuvant tislelizumab plus chemoradiotherapy shows clinical promise for locally advanced gastric or gastroesophageal junction cancer.
Phase 2b results from the...
01/13/2026
Oncology
News
Zolbetuximab Plus mFOLFOX6 and Nivolumab Shows Promise for CLDN18.2-Positive Gastric and Gastroesophageal Junction Adenocarcinoma
01/08/2026
Stephanie Holland
Zolbetuximab plus mFLOFOX and nivolumab demonstrated clinical promise among HER2-negative patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma with high CLDN18.2 expression, according...
Zolbetuximab plus mFLOFOX and nivolumab demonstrated clinical promise among HER2-negative patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma with high CLDN18.2 expression, according...
Zolbetuximab plus mFLOFOX and...
01/08/2026
Oncology
News
Frontline Zanidatamab-Based Treatment Demonstrates Promise for HER2-Positive Metastatic Gastroesophageal Adenocarcinoma
01/08/2026
Stephanie Holland
According to results from the phase 3 HERIZON-GEA-01 trial, zanidatamab-based treatment demonstrates a promising survival benefit among previously untreated patients with HER2-positive metastatic gastroesophageal adenocarcinoma.
According to results from the phase 3 HERIZON-GEA-01 trial, zanidatamab-based treatment demonstrates a promising survival benefit among previously untreated patients with HER2-positive metastatic gastroesophageal adenocarcinoma.
According to results from the...
01/08/2026
Oncology
News
First-Line Capecitabine Plus Carboplatin Reduces Neurotoxicity Without Compromising Efficacy in Metastatic HER2-Negative Esophagogastric Adenocarcinoma
01/08/2026
Stephanie Holland
According to results from a multicenter phase 2 trial, first-line capecitabine plus carboplatin improved outcomes among previously untreated patients with metastatic or unresectable HER2-negative esophagogastric adenocarcinoma.
According to results from a multicenter phase 2 trial, first-line capecitabine plus carboplatin improved outcomes among previously untreated patients with metastatic or unresectable HER2-negative esophagogastric adenocarcinoma.
According to results from a...
01/08/2026
Oncology
News
Bemarituzumab Added to Chemotherapy Significantly Benefits Survival in FGFR2b-Positive Gastric and GEJ Cancer
10/20/2025
Stephanie Holland
Results from the phase 3 FORTITUDE-101 trial show adding bemarituzumab to mFOLFOX6 significantly improved survival among patients with unresectable, locally advanced or metastatic FGFR2b expressing gastric or gastroesophageal junction (GEJ)...
Results from the phase 3 FORTITUDE-101 trial show adding bemarituzumab to mFOLFOX6 significantly improved survival among patients with unresectable, locally advanced or metastatic FGFR2b expressing gastric or gastroesophageal junction (GEJ)...
Results from the phase 3...
10/20/2025
Oncology
News
Lenvatinib Added to Pembrolizumab and Chemotherapy Fails to Improve OS in Metastatic Esophageal Squamous Cell Carcinoma
10/17/2025
Stephanie Holland
Second interim analysis results from the phase 3 LEAP-014 trial found that the addition of lenvatinib to pembrolizumab plus chemotherapy did not significantly improve survival among patients with previously untreated metastatic esophageal...
Second interim analysis results from the phase 3 LEAP-014 trial found that the addition of lenvatinib to pembrolizumab plus chemotherapy did not significantly improve survival among patients with previously untreated metastatic esophageal...
Second interim analysis results...
10/17/2025
Oncology
News
Anbenitamab Plus Chemotherapy Significantly Improves Survival in Previously Treated HER2-Positive Gastric or GEJ Cancer
10/17/2025
Janelle Bradley
Anbenitamab plus chemotherapy significantly improved OS and PFS, with a threefold higher response rate vs chemotherapy alone, in patients with previously treated HER2-positive gastric or GEJ cancer.
Anbenitamab plus chemotherapy significantly improved OS and PFS, with a threefold higher response rate vs chemotherapy alone, in patients with previously treated HER2-positive gastric or GEJ cancer.
Anbenitamab plus chemotherapy...
10/17/2025
Oncology

News

News
Zanidatamab Plus Tislelizumab Improves Survival in HER2-Positive Advanced Gastroesophageal Adenocarcinoma
06/10/2026
Emily Estrada
Results from the HERIZON-GEA-01 trial demonstrated that zanidatamab plus chemotherapy with or without tislelizumab significantly improved outcomes in patients with HER2-positive advanced gastroesophageal adenocarcinoma.
Results from the HERIZON-GEA-01 trial demonstrated that zanidatamab plus chemotherapy with or without tislelizumab significantly improved outcomes in patients with HER2-positive advanced gastroesophageal adenocarcinoma.
Results from the HERIZON-GEA-01...
06/10/2026
Oncology
News
Five-Year Follow-up Confirms Survival Benefit With Nivolumab Plus Chemotherapy in Gastroesophageal Adenocarcinoma
02/12/2026
Stephanie Holland
Five-year follow-up from the phase 3 CheckMate 649 trial demonstrated that nivolumab plus chemotherapy continued to improve survival compared with chemotherapy alone in patients with previously untreated, HER2-negative unresectable or...
Five-year follow-up from the phase 3 CheckMate 649 trial demonstrated that nivolumab plus chemotherapy continued to improve survival compared with chemotherapy alone in patients with previously untreated, HER2-negative unresectable or...
Five-year follow-up from the...
02/12/2026
Oncology
News
Anbenitamab Plus Chemotherapy Improves Survival After Trastuzumab in HER2-Positive Gastric and Gastroesophageal Junction Cancer
01/21/2026
Stephanie Holland
Results from a phase 3 trial demonstrated that anbenitamab plus chemotherapy significantly improved progression-free and overall survival compared with placebo plus chemotherapy in patients with previously treated HER2-positive gastric or...
Results from a phase 3 trial demonstrated that anbenitamab plus chemotherapy significantly improved progression-free and overall survival compared with placebo plus chemotherapy in patients with previously treated HER2-positive gastric or...
Results from a phase 3 trial...
01/21/2026
Oncology
News
Addition of Tislelizumab to Neoadjuvant Chemoradiotherapy Shows Clinical Promise for Gastric/GEJ Cancer
01/13/2026
Stephanie Holland
Phase 2b results from the TERRIFIC study demonstrate that neoadjuvant tislelizumab plus chemoradiotherapy shows clinical promise for locally advanced gastric or gastroesophageal junction cancer.
Phase 2b results from the TERRIFIC study demonstrate that neoadjuvant tislelizumab plus chemoradiotherapy shows clinical promise for locally advanced gastric or gastroesophageal junction cancer.
Phase 2b results from the...
01/13/2026
Oncology
News
Zolbetuximab Plus mFOLFOX6 and Nivolumab Shows Promise for CLDN18.2-Positive Gastric and Gastroesophageal Junction Adenocarcinoma
01/08/2026
Stephanie Holland
Zolbetuximab plus mFLOFOX and nivolumab demonstrated clinical promise among HER2-negative patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma with high CLDN18.2 expression, according...
Zolbetuximab plus mFLOFOX and nivolumab demonstrated clinical promise among HER2-negative patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma with high CLDN18.2 expression, according...
Zolbetuximab plus mFLOFOX and...
01/08/2026
Oncology
News
Frontline Zanidatamab-Based Treatment Demonstrates Promise for HER2-Positive Metastatic Gastroesophageal Adenocarcinoma
01/08/2026
Stephanie Holland
According to results from the phase 3 HERIZON-GEA-01 trial, zanidatamab-based treatment demonstrates a promising survival benefit among previously untreated patients with HER2-positive metastatic gastroesophageal adenocarcinoma.
According to results from the phase 3 HERIZON-GEA-01 trial, zanidatamab-based treatment demonstrates a promising survival benefit among previously untreated patients with HER2-positive metastatic gastroesophageal adenocarcinoma.
According to results from the...
01/08/2026
Oncology
News
First-Line Capecitabine Plus Carboplatin Reduces Neurotoxicity Without Compromising Efficacy in Metastatic HER2-Negative Esophagogastric Adenocarcinoma
01/08/2026
Stephanie Holland
According to results from a multicenter phase 2 trial, first-line capecitabine plus carboplatin improved outcomes among previously untreated patients with metastatic or unresectable HER2-negative esophagogastric adenocarcinoma.
According to results from a multicenter phase 2 trial, first-line capecitabine plus carboplatin improved outcomes among previously untreated patients with metastatic or unresectable HER2-negative esophagogastric adenocarcinoma.
According to results from a...
01/08/2026
Oncology
News
Bemarituzumab Added to Chemotherapy Significantly Benefits Survival in FGFR2b-Positive Gastric and GEJ Cancer
10/20/2025
Stephanie Holland
Results from the phase 3 FORTITUDE-101 trial show adding bemarituzumab to mFOLFOX6 significantly improved survival among patients with unresectable, locally advanced or metastatic FGFR2b expressing gastric or gastroesophageal junction (GEJ)...
Results from the phase 3 FORTITUDE-101 trial show adding bemarituzumab to mFOLFOX6 significantly improved survival among patients with unresectable, locally advanced or metastatic FGFR2b expressing gastric or gastroesophageal junction (GEJ)...
Results from the phase 3...
10/20/2025
Oncology
News
Lenvatinib Added to Pembrolizumab and Chemotherapy Fails to Improve OS in Metastatic Esophageal Squamous Cell Carcinoma
10/17/2025
Stephanie Holland
Second interim analysis results from the phase 3 LEAP-014 trial found that the addition of lenvatinib to pembrolizumab plus chemotherapy did not significantly improve survival among patients with previously untreated metastatic esophageal...
Second interim analysis results from the phase 3 LEAP-014 trial found that the addition of lenvatinib to pembrolizumab plus chemotherapy did not significantly improve survival among patients with previously untreated metastatic esophageal...
Second interim analysis results...
10/17/2025
Oncology
News
Anbenitamab Plus Chemotherapy Significantly Improves Survival in Previously Treated HER2-Positive Gastric or GEJ Cancer
10/17/2025
Janelle Bradley
Anbenitamab plus chemotherapy significantly improved OS and PFS, with a threefold higher response rate vs chemotherapy alone, in patients with previously treated HER2-positive gastric or GEJ cancer.
Anbenitamab plus chemotherapy significantly improved OS and PFS, with a threefold higher response rate vs chemotherapy alone, in patients with previously treated HER2-positive gastric or GEJ cancer.
Anbenitamab plus chemotherapy...
10/17/2025
Oncology

Interactive Features

Quiz
Quiz: Which chemotherapy regimen was found to be the standard first-line option for patients with advanced neuroendocrine carcinomas of the digestive system?
10/17/2022
Do you know which chemotherapy regimen was found to be the standard first-line option for patients with advanced neuroendocrine carcinomas of the digestive system?
Do you know which chemotherapy regimen was found to be the standard first-line option for patients with advanced neuroendocrine carcinomas of the digestive system?
Do you know which chemotherapy...
10/17/2022
Oncology
Test Your Knowledge
Quiz: Identifying Biliary Tract Cancers
09/08/2021
Which of the following uncommon cancers are classified as biliary tract cancers?
Which of the following uncommon cancers are classified as biliary tract cancers?
Which of the following uncommon...
09/08/2021
Oncology
Quiz
Quiz: Does Atorvastatin-Metformin Combo Reduce HCC Progression?
08/09/2021
True or false: The combination of atorvastatin and metformin have been shown to reduce the progression of chronic active hepatitis and cirrhosis to hepatocellular carcinoma, as well as increase the power of sorafenib, and develops a direct...
True or false: The combination of atorvastatin and metformin have been shown to reduce the progression of chronic active hepatitis and cirrhosis to hepatocellular carcinoma, as well as increase the power of sorafenib, and develops a direct...
True or false: The combination...
08/09/2021
Oncology
Test Your Knowledge
Quiz: Anlotinib Therapy for Chinese Patients with Mutated CRC
01/28/2021
True or false: Anlotinib has shown benefit in Chinese patients with refractory metastatic RAS/KRAS/BRAF-wildtype colorectal cancer.
True or false: Anlotinib has shown benefit in Chinese patients with refractory metastatic RAS/KRAS/BRAF-wildtype colorectal cancer.
True or false: Anlotinib has...
01/28/2021
Oncology
Test Your Knowledge
Quiz: Does Infigratinib Yield a Survival Benefit in Patients with Cholangiocarcinoma and FGFR2 Fusions?
08/28/2020
True or false: Infigratinib did not yield a survival benefit in patients with cholangiocarcinoma and FGFR2 fusions.
True or false: Infigratinib did not yield a survival benefit in patients with cholangiocarcinoma and FGFR2 fusions.
True or false: Infigratinib did...
08/28/2020
Oncology
Test Your Knowledge
Quiz: Is Avapritinib a Treatment Option for Patients with Unresectable PDGFRA D842V-Mutant GIST?
08/21/2020
True or false: In patients with unresectable PDGFRA D842V-Mutant GIST, avapritinib did not demonstrate meaningful activity.
True or false: In patients with unresectable PDGFRA D842V-Mutant GIST, avapritinib did not demonstrate meaningful activity.
True or false: In patients with...
08/21/2020
Oncology
Test Your Knowledge
Quiz: Is Differentiating Tumor Tissue from Pure Fibrosis Possible During Surgery for CRC?
08/21/2020
True or false: Classifying and differentiating tumor tissue from pure fibrosis during surgery for CRC is possible.
True or false: Classifying and differentiating tumor tissue from pure fibrosis during surgery for CRC is possible.
True or false: Classifying and...
08/21/2020
Oncology
Test Your Knowledge
Quiz: Is Oxaliplatin Superior to Mitomycin C During HIPEC for Colorectal Peritoneal Metastases?
07/31/2020
True or false: Overall survival disparity exists between the use of oxaliplatin and mitomycin C during CRS-HIPEC for colorectal peritoneal metastases.
True or false: Overall survival disparity exists between the use of oxaliplatin and mitomycin C during CRS-HIPEC for colorectal peritoneal metastases.
True or false: Overall survival...
07/31/2020
Oncology
Test Your Knowledge
Quiz: Can Plasma MDMs Accurately Detect Distant Recurrent CRC?
06/22/2020
True or False: MDMs in plasma show promise as a method for accurately detecting distant recurrent CRC.
True or False: MDMs in plasma show promise as a method for accurately detecting distant recurrent CRC.
True or False: MDMs in plasma...
06/22/2020
Oncology
Test Your Knowledge
Quiz: Should Pembrolizumab Be New Standard of Care for MSI-H/dMMR Metastatic CRC?
06/04/2020
True or False: Pembrolizumab should be the new standard of care for MSI-H/dMMR metastatic colorectal cancer?
True or False: Pembrolizumab should be the new standard of care for MSI-H/dMMR metastatic colorectal cancer?
True or False: Pembrolizumab...
06/04/2020
Oncology

Recent News

News
Zanidatamab Plus Tislelizumab Improves Survival in HER2-Positive Advanced Gastroesophageal Adenocarcinoma
06/10/2026
Emily Estrada
Results from the HERIZON-GEA-01 trial demonstrated that zanidatamab plus chemotherapy with or without tislelizumab significantly improved outcomes in patients with HER2-positive advanced gastroesophageal adenocarcinoma.
Results from the HERIZON-GEA-01 trial demonstrated that zanidatamab plus chemotherapy with or without tislelizumab significantly improved outcomes in patients with HER2-positive advanced gastroesophageal adenocarcinoma.
Results from the HERIZON-GEA-01...
06/10/2026
Oncology
News
Five-Year Follow-up Confirms Survival Benefit With Nivolumab Plus Chemotherapy in Gastroesophageal Adenocarcinoma
02/12/2026
Stephanie Holland
Five-year follow-up from the phase 3 CheckMate 649 trial demonstrated that nivolumab plus chemotherapy continued to improve survival compared with chemotherapy alone in patients with previously untreated, HER2-negative unresectable or...
Five-year follow-up from the phase 3 CheckMate 649 trial demonstrated that nivolumab plus chemotherapy continued to improve survival compared with chemotherapy alone in patients with previously untreated, HER2-negative unresectable or...
Five-year follow-up from the...
02/12/2026
Oncology
News
Anbenitamab Plus Chemotherapy Improves Survival After Trastuzumab in HER2-Positive Gastric and Gastroesophageal Junction Cancer
01/21/2026
Stephanie Holland
Results from a phase 3 trial demonstrated that anbenitamab plus chemotherapy significantly improved progression-free and overall survival compared with placebo plus chemotherapy in patients with previously treated HER2-positive gastric or...
Results from a phase 3 trial demonstrated that anbenitamab plus chemotherapy significantly improved progression-free and overall survival compared with placebo plus chemotherapy in patients with previously treated HER2-positive gastric or...
Results from a phase 3 trial...
01/21/2026
Oncology
News
Addition of Tislelizumab to Neoadjuvant Chemoradiotherapy Shows Clinical Promise for Gastric/GEJ Cancer
01/13/2026
Stephanie Holland
Phase 2b results from the TERRIFIC study demonstrate that neoadjuvant tislelizumab plus chemoradiotherapy shows clinical promise for locally advanced gastric or gastroesophageal junction cancer.
Phase 2b results from the TERRIFIC study demonstrate that neoadjuvant tislelizumab plus chemoradiotherapy shows clinical promise for locally advanced gastric or gastroesophageal junction cancer.
Phase 2b results from the...
01/13/2026
Oncology
News
Zolbetuximab Plus mFOLFOX6 and Nivolumab Shows Promise for CLDN18.2-Positive Gastric and Gastroesophageal Junction Adenocarcinoma
01/08/2026
Stephanie Holland
Zolbetuximab plus mFLOFOX and nivolumab demonstrated clinical promise among HER2-negative patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma with high CLDN18.2 expression, according...
Zolbetuximab plus mFLOFOX and nivolumab demonstrated clinical promise among HER2-negative patients with locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma with high CLDN18.2 expression, according...
Zolbetuximab plus mFLOFOX and...
01/08/2026
Oncology
News
Frontline Zanidatamab-Based Treatment Demonstrates Promise for HER2-Positive Metastatic Gastroesophageal Adenocarcinoma
01/08/2026
Stephanie Holland
According to results from the phase 3 HERIZON-GEA-01 trial, zanidatamab-based treatment demonstrates a promising survival benefit among previously untreated patients with HER2-positive metastatic gastroesophageal adenocarcinoma.
According to results from the phase 3 HERIZON-GEA-01 trial, zanidatamab-based treatment demonstrates a promising survival benefit among previously untreated patients with HER2-positive metastatic gastroesophageal adenocarcinoma.
According to results from the...
01/08/2026
Oncology
News
First-Line Capecitabine Plus Carboplatin Reduces Neurotoxicity Without Compromising Efficacy in Metastatic HER2-Negative Esophagogastric Adenocarcinoma
01/08/2026
Stephanie Holland
According to results from a multicenter phase 2 trial, first-line capecitabine plus carboplatin improved outcomes among previously untreated patients with metastatic or unresectable HER2-negative esophagogastric adenocarcinoma.
According to results from a multicenter phase 2 trial, first-line capecitabine plus carboplatin improved outcomes among previously untreated patients with metastatic or unresectable HER2-negative esophagogastric adenocarcinoma.
According to results from a...
01/08/2026
Oncology
News
Bemarituzumab Added to Chemotherapy Significantly Benefits Survival in FGFR2b-Positive Gastric and GEJ Cancer
10/20/2025
Stephanie Holland
Results from the phase 3 FORTITUDE-101 trial show adding bemarituzumab to mFOLFOX6 significantly improved survival among patients with unresectable, locally advanced or metastatic FGFR2b expressing gastric or gastroesophageal junction (GEJ)...
Results from the phase 3 FORTITUDE-101 trial show adding bemarituzumab to mFOLFOX6 significantly improved survival among patients with unresectable, locally advanced or metastatic FGFR2b expressing gastric or gastroesophageal junction (GEJ)...
Results from the phase 3...
10/20/2025
Oncology
News
Anbenitamab Plus Chemotherapy Significantly Improves Survival in Previously Treated HER2-Positive Gastric or GEJ Cancer
10/17/2025
Janelle Bradley
Anbenitamab plus chemotherapy significantly improved OS and PFS, with a threefold higher response rate vs chemotherapy alone, in patients with previously treated HER2-positive gastric or GEJ cancer.
Anbenitamab plus chemotherapy significantly improved OS and PFS, with a threefold higher response rate vs chemotherapy alone, in patients with previously treated HER2-positive gastric or GEJ cancer.
Anbenitamab plus chemotherapy...
10/17/2025
Oncology
News
Durvalumab Plus FLOT Improves OS in Resectable Gastric and GEJ Adenocarcinoma
10/17/2025
Janelle Bradley
The phase 3 MATTERHORN trial showed that adding durvalumab to perioperative FLOT significantly improved OS and EFS vs FLOT alone in resectable gastric and GEJ adenocarcinoma, with benefits observed regardless of PD-L1 status.
The phase 3 MATTERHORN trial showed that adding durvalumab to perioperative FLOT significantly improved OS and EFS vs FLOT alone in resectable gastric and GEJ adenocarcinoma, with benefits observed regardless of PD-L1 status.
The phase 3 MATTERHORN trial...
10/17/2025
Oncology
News
Indefinite Lenalidomide Maintenance Fails to Improve Overall Survival in Standard-Risk Multiple Myeloma
07/16/2026
Stephanie Holland
Results from the phase 3 ENDURANCE trial demonstrated that indefinite-duration lenalidomide maintenance therapy did not improve overall survival compared with 2 years of maintenance therapy in patients with standard-risk newly diagnosed...
Results from the phase 3 ENDURANCE trial demonstrated that indefinite-duration lenalidomide maintenance therapy did not improve overall survival compared with 2 years of maintenance therapy in patients with standard-risk newly diagnosed...
Results from the phase 3...
07/16/2026
Oncology
News
Dostarlimab Meets Primary End Point in Registrational AZUR-1 Trial for dMMR/MSI-H Rectal Cancer
07/16/2026
Stephanie Holland
Interim results from the registrational phase 2 AZUR-1 trial demonstrated that dostarlimab monotherapy achieved a clinically meaningful and durable clinical complete response in patients with stage II/III mismatch...
Interim results from the registrational phase 2 AZUR-1 trial demonstrated that dostarlimab monotherapy achieved a clinically meaningful and durable clinical complete response in patients with stage II/III mismatch...
Interim results from the...
07/16/2026
Oncology
FDA Approval
FDA Approves Gedatolisib-Based Regimens for PIK3CA Wild-Type HR-Positive, HER2-Negative Advanced Breast Cancer
07/14/2026
Stephanie Holland
The FDA approved gedatolisib in combination with fulvestrant, with or without palbociclib, for patients with PIK3CA wild-type HR-positive, HER2-negative advanced or metastatic breast cancer based on the phase 3 VIKTORIA-1 trial demonstrating...
The FDA approved gedatolisib in combination with fulvestrant, with or without palbociclib, for patients with PIK3CA wild-type HR-positive, HER2-negative advanced or metastatic breast cancer based on the phase 3 VIKTORIA-1 trial demonstrating...
The FDA approved gedatolisib in...
07/14/2026
Oncology
FDA Approval
FDA Grants Traditional Approval to Selpercatinib for RET Fusion-Positive Solid Tumors
07/14/2026
Stephanie Holland
The FDA granted traditional approval to selpercatinib for adults and children aged 2 years and older with previously treated RET fusion-positive solid tumors based on durable responses observed across multiple tumor types in the LIBRETTO-001...
The FDA granted traditional approval to selpercatinib for adults and children aged 2 years and older with previously treated RET fusion-positive solid tumors based on durable responses observed across multiple tumor types in the LIBRETTO-001...
The FDA granted traditional...
07/14/2026
Oncology
News
De-escalated Paclitaxel, Trastuzumab, and Pertuzumab Yield Excellent Long-Term Outcomes in HER2-Positive Breast Cancer
07/14/2026
Stephanie Holland
A prespecified analysis of the phase 2 DAPHNe trial demonstrated that abbreviated neoadjuvant paclitaxel, trastuzumab, and pertuzumab produced excellent 5-year outcomes in stage II to III HER2-positive breast cancer, while ultrasensitive...
A prespecified analysis of the phase 2 DAPHNe trial demonstrated that abbreviated neoadjuvant paclitaxel, trastuzumab, and pertuzumab produced excellent 5-year outcomes in stage II to III HER2-positive breast cancer, while ultrasensitive...
A prespecified analysis of the...
07/14/2026
Oncology
FDA Approval
FDA Approves Pegfilgrastim Biosimilar ENNUMO for the Prevention of Febrile Neutropenia and Treatment of Acute Radiation Syndrome
07/13/2026
Stephanie Holland
The FDA approved ENNUMO, a biosimilar to pegfilgrastim, for the same indications as the reference product, providing an additional granulocyte colony-stimulating factor option to reduce febrile neutropenia during myelosuppressive chemotherapy...
The FDA approved ENNUMO, a biosimilar to pegfilgrastim, for the same indications as the reference product, providing an additional granulocyte colony-stimulating factor option to reduce febrile neutropenia during myelosuppressive chemotherapy...
The FDA approved ENNUMO, a...
07/13/2026
Oncology
FDA Alerts
FDA Accepts New Drug Application for Mezigdomide Combination in Relapsed or Refractory Multiple Myeloma
07/13/2026
Stephanie Holland
The FDA accepted the new drug application for mezigdomide plus carfilzomib and dexamethasone for relapsed or refractory multiple myeloma based on phase 3 SUCCESSOR-2 results demonstrating a significant progression-free survival benefit...
The FDA accepted the new drug application for mezigdomide plus carfilzomib and dexamethasone for relapsed or refractory multiple myeloma based on phase 3 SUCCESSOR-2 results demonstrating a significant progression-free survival benefit...
The FDA accepted the new drug...
07/13/2026
Oncology
News
Trastuzumab Rezetecan Improves Progression-Free Survival in Previously Treated HER2-Positive Metastatic Breast Cancer
07/10/2026
Stephanie Holland
Interim results from the phase 3 HORIZON-Breast01 trial demonstrated that trastuzumab rezetecan significantly improved progression-free survival compared with pyrotinib plus capecitabine in patients with previously treated HER2-positive...
Interim results from the phase 3 HORIZON-Breast01 trial demonstrated that trastuzumab rezetecan significantly improved progression-free survival compared with pyrotinib plus capecitabine in patients with previously treated HER2-positive...
Interim results from the phase...
07/10/2026
Oncology
FDA Approval
FDA Approves Subcutaneous Isatuximab Across Multiple Indications for Patients With Multiple Myeloma
07/10/2026
Emily Estrada
The FDA has approved subcutaneous isatuximab for three treatment indications in multiple myeloma, including in combination with pomalidomide and dexamethasone, carfilzomib and dexamethasone, or bortezomib, lenalidomide, and dexamethasone.
The FDA has approved subcutaneous isatuximab for three treatment indications in multiple myeloma, including in combination with pomalidomide and dexamethasone, carfilzomib and dexamethasone, or bortezomib, lenalidomide, and dexamethasone.
The FDA has approved...
07/10/2026
Oncology
News
Performance Status Predicts Real-World Outcomes With Tarlatamab in Extensive-Stage Small Cell Lung Cancer
07/09/2026
Stephanie Holland
A multicenter real-world study identified ECOG performance status as a key determinant of outcomes with tarlatamab in extensive-stage small cell lung cancer, with patients who had preserved functional status achieving survival comparable to...
A multicenter real-world study identified ECOG performance status as a key determinant of outcomes with tarlatamab in extensive-stage small cell lung cancer, with patients who had preserved functional status achieving survival comparable to...
A multicenter real-world study...
07/09/2026
Oncology

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use